-
Product Insights
NewPulmonary Tuberculosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Pulmonary Tuberculosis Clinical Trial Report Overview A total of 504 pulmonary tuberculosis clinical trials were conducted as of April 2024. The pulmonary tuberculosis clinical trial report provides a comprehensive understanding of the pulmonary tuberculosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·      North America ·      ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Treprostinil in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil in Pulmonary Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil in Pulmonary Hypertension Drug Details: Treprostinil (Yutrepia) is a prostacyclin analog...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Treprostinil in Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil in Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil in Pulmonary Fibrosis Drug Details: Treprostinil (Tyvaso, Tyvaso DPI) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pulmonary Sarcoidosis Drug Details: Canakinumab (Ilaris / Lasprona /...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Macitentan in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Macitentan in Pulmonary Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macitentan in Pulmonary Hypertension Drug Details: Macitentan (Opsumit, Zependo) is a novel...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Staphylokinase in Pulmonary Embolism
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Staphylokinase in Pulmonary Embolism report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Staphylokinase in Pulmonary Embolism Drug Details: Staphylokinase (fortelyzin) is an enzyme secreted...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Pulmonary Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Pulmonary Hypertension Drug Details: Levosimendan (Simdax, Zimino) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axatilimab in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axatilimab in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axatilimab in Idiopathic Pulmonary Fibrosis Drug Details: Axatilimab (SNDX-6352) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taladegib in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taladegib in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Taladegib in Idiopathic Pulmonary Fibrosis Drug Details: Taladegib (LY-2940680) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitiperstat in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitiperstat in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitiperstat in Pulmonary Arterial Hypertension Drug Details: Mitiperstat is under development...